Acute angioedema in Cape Town emergency centres and a suggested algorithm to simplify and improve management
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i8.717Keywords:
angiotensin converting enzyme inhibitor, acute angioedema, medical emergencies management plan, drug induced angioedema, mast cell mediated angioedema, bradykinin mediated angioedemaAbstract
Background. Angioedema is the most common acute allergic presentation to emergency centres (EC), with hospitalisation rates increasing in high-income countries. Angioedema can complicate with life-threatening laryngeal obstruction. There are no local data; therefore, we aimed to characterise acute angioedema cases presenting to ECs and develop a simple management algorithm.
Objective. To characterise the clinical presentation, management and outcomes of acute angioedema cases presenting to ECs. Based on these findings, we developed a management algorithm for acute angioedema to improve the care of acute angioedema in South Africa (SA).
Methods. We conducted a retrospective folder review of all patients admitted to Groote Schuur Hospital (tertiary) and Mitchells Plain District Hospital (secondary) ECs from 1 June 2018 to 31 June 2020. Using ICD-10 coding, folders of adults ≥18 years with possible angioedema presenting to the ECs were screened. An allergist extracted demographics, medical history, management and outcome data for each angioedema event.
Results. A total of 142 acute angioedema episodes were included, with a median (interquartile range) age of 42 (28 - 58) years, and 62% of patients were female. The majority (124/142, 87%) of acute angioedema EC presentations involved swelling above the shoulders, with airway involvement in 20 (14%) patients, with two patients requiring intubation. Nineteen (13%) patients required admission, with five (26%) admitted to high care/intensive care. Drug-induced angioedema was the most common cause, with 64/142 (45%) linked to a known offending drug, 42/64 (65.6%) being angiotensin-converting enzyme inhibitor (ACE-I). Critical information to guide angioedema management, including past personal/family allergy history, and duration of angioedema prior to EC visit, was not recorded in 64.7% and 37.8% of EC records, respectively. Unnecessary treatment with corticosteroids or antihistamines occurred in 19/53 (36%) and 16/53 (30%) cases with bradykinin-mediated angioedema ACE-I angioedema and hereditary angioedema). Overall, only 36/142 (25%) of angioedema patients were connected to allergy care.
Conclusion. Angioedema is the most common allergy presentation to two ECs in Cape Town, SA. Bradykinin-mediated angioedema secondary to ACE-I therapy is the single most common offender, and was not appropriately managed in more than a third of cases. Based on these findings, we have developed a management algorithm that easily stratifies patients into bradykinin or mast cell-mediated angioedema with a step-by-step management approach that is applicable to the SA context. Ongoing awareness and education on allergy emergencies are required to ensure accurate diagnosis of less common causes of angioedema (particularly bradykinin-mediated angioedema) and linkage to allergy specialist care.
References
Cicardi M, Suffritti C, Perego F, Caccia S. Novelties in the diagnosis and treatment of angioedema.
J Investig Allergol Clin Immunol 2016;26(4):212-221. https://doi.org/10.18176/jiaci.0087
Smith A, Ray M, Jain N, Zhang H, Sebelik M. The burden of angioedema on United States
emergency departments: 2006-2010. Laryngoscope 2017;127(4):828-834. https://doi.org/10.1002/
lary.26336
Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin
converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996;60(1):8-13.
https://doi.org/10.1016/s0009-9236(96)90161-7
Javaud N, Karami A, Stirnemann J, et al. Bradykinin-mediated angioedema: Factors prompting ED
visits. Am J Emerg Med 2013;31(1):124-129. https://doi.org/10.1016/j.ajem.2012.06.021
Stauber T, Confino-Cohen R, Goldberg A. Life-threatening angioedema induced by angiotensinconverting enzyme inhibitors: Characteristics and risk factors. Am J Rhinol Allergy 2014;28(1):54-
https://doi.org/10.2500/ajra.2014.28.3989
Sandefur BJ, Silva LOJE, Lohse CM, et al. Clinical features and outcomes associated with
angioedema in the emergency department. W J Emerg Med 2019;20(5):760-769. https://doi.
org/10.5811/westjem.2019.6.42852
Kamerman P. Underdiagnosis of hypertension and diabetes mellitus in South Africa. S Afr Med J
;112(1):53-50. https://doi.org/10.7196/SAMJ.2022.v112i1.15968
Macrotrends. Cape Town, South Africa Metro Area Population 1950-2022. Macrotrends, 2022.
https://www.macrotrends.net/cities/22481/cape-town/population (accessed 30 September 2022).
Department of Cooperative Government and Traditional Affairs, South Africa. West Coast
District Municipality Western Cape, profile and analysis district development model. Pretoria:
COGTA, 2020. https://www.cogta.gov.za/ddm/wp-content/uploads/2020/11/Westcoast-DMSeptember-2020.pdf (accessed 30 September 2022).
Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization anaphylaxis guidance 2020.
World Allergy Org J 2020;13(10):100472. https://doi.org/10.1016/j.waojou.2020.100472
Kim SJ, Brooks JC, Sheikh J, Kaplan MS, Goldberg BJ. Angioedema deaths in the United States,
-2010. Ann Allergy Asthma Immunol 2014;113(6):630-634. https://doi.org/10.1016/j.
anai.2014.09.003
Depetri F, Tedeschi A, Cugno M. Angioedema and emergency medicine: From pathophysiology
to diagnosis and treatment. Eur J Int Med 2019;59:8-13. https://doi.org/10.1016/j.ejim.2018.09.004
Barker S, Daniels L, Chang Y-S, et al. Allergy education and training for physicians. World Allergy
Org J 2021;14(10):100589. https://doi.org/10.1016%2Fj.waojou.2021.100589
Lombardi C, Crivellaro M, Dama A, Senna G, Gargioni S, Passalacqua G. Are physicians aware of
the side effects of angiotensin-converting enzyme inhibitors?: A questionnaire survey in different
medical categories. Chest 2005;128(2):976-979. https://doi.org/10.1378/chest.128.2.97
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Cascia Day, Jonny, Janet, Clint Hendrikse, Kenneth Crombie
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
